|
Jing
Shen, Yao-Chu Xu, Xin-Ru Wang, Department of Epidemiology &
Biostatistics, School of Public Health, Nanjing Medical University,
Nanjing 210029, Jiangsu Province, China
Run-Tian Wang, Health Science Center, Peking University,
Beijing 100083, China
Li-Wei Wang, Yangzhong Cancer Research Institute, Yangzhong
212200, Jiangsu Province, China
Supported by Grants From the National Natural Science
Foundation of China (30170827 to Jing. Shen and 30070671 to Run-Tian
Wang)
Correspondence to: Jing Shen, Department of Environmental
Health Sciences, Mailman School of Public Health, Columbia
University, 701 West 168th St (Room 505), New York, NY 10032,
USA. js2182@columbia.edu
Telephone: +212-305-8158
Fax: +212-305-5328
Received: 2003-07-12
Accepted: 2003-10-12
Abstract
AIM: Inducible nitric oxide synthase (iNOS) plays a central role
in the pathway of reactive oxygen and nitrogen species metabolism
when Helicobacter pylori (H pylori) infection occurs
in humans. iNOS Ser608Leu allele, a novel genetic
polymorphism (C/T) occurring within exon 16 of the iNOS reductase
domain, may have a dramatic effect on the enzymatic activity. The
aim of this study was to determine whether iNOS C/T polymorphism was
associated with increased susceptibility to gastric cancer.
METHODS: We conducted a population based case-control study in a
high gastric cancer incidence area, Yangzhong, China. Questionnaires
from 93 patients with intestinal type gastric cancer (IGC), 50 with
gastric cardia cancer (GCC) and 246 healthy controls were obtained
between 1997 and 1998, and iNOS genotyping was carried out. Odds
ratios (ORs), interaction index (g),
and 95% confidence intervals for the combined effects of iNOS
genotype and H pylori infection, cigarette smoking or alcohol
drinking were estimated.
RESULTS: The frequency of (CT+TT) genotypes was higher in cases than
in control group (24.48% vs 23.17%), but the difference was not
statistically significant. After adjusting for age and gender, past
cigarette smokers with (CT+TT) genotypes had a significantly
increased risk of IGC (OR = 3.62, 95% CI: 1.23-10.64), while past
alcohol drinkers with (CT+TT) genotypes had a significantly
increased risk of GCC (OR = 3.33, 95% CI: 1.14-9.67). H pylori
CagA negative subjects with (CT+TT) genotypes had a significantly
increased risk of both IGC and GCC (OR = 2.19 and 3.52,
respectively).
CONCLUSION: iNOS Ser608Leu allele may be a potential
determinant of susceptibility to cigarette -alcohol induced gastric
cancer, but larger studies are needed to confirm the observations.
Shen J, Wang RT, Wang
LW, Xu YC, Wang XR. A novel genetic polymorphism of inducible nitric
oxide synthase is associated with an increased risk of gastric
cancer. World J Gastroenterol 2004;
10(22): 3278-3283
http://www.wjgnet.com/1007-9327/10/3278.asp
INTRODUCTION
On a global scale, gastric cancer remains the world’s second
most common malignancy. There is a substantial international
variation in gastric cancer incidence with the highest rates
reported from China, Japan and other Eastern Asian countries[1].
The discovery of Helicobacter pylori (H pylori) in the
early 1980 s has been proven to be a turning point in understanding
the pathogenesis of this malignancy. A major advance in this field
came with the recognition that chronic H pylori infection
could induce physiologic and morphologic changes within the gastric
milieu, which increase the risk of neoplastic transformation[2].
It has been widely accepted that chronic H pylori infection
induces hypochlorhydria and gastric atrophy, both of which are
precursors of gastric cancer[2]. Epidemiological studies
have also indicated that infection with H pylori is
considered as a risk factor for gastric cancer[3,4] and
the WHO IARC has classified this bacterium as a definite biological
carcinogen[5]. However, while the majority of infected
individuals develop no significant clinical disease, others develop
two kinds of divergent clinical outcomes-peptic ulcer disease and
gastric cancer[2]. The reasons for developing these two
extreme phenotypes, especially important in gastric cancer, have
remained poorly understood, and are not explained by bacterial
virulence factors alone[2]. This highlights the need to
explore potential candidate genes of the host in the pathways
involved in the natural history of H pylori infection and its
interactions with other risk factors in the development of gastric
cancer in a high-risk population.
The inducible form of nitric oxide (NO) synthase (iNOS) is
one of the most important enzymes involved in the pathway of
reactive oxygen and nitrogen species metabolism in the presence of H
pylori infection in humans. iNOS is a major source of NO
production that is produced during inflammation by macrophages[6,7].
Expression of iNOS in response to cytokines is part of the
inflammatory response and contributes to tissue damage, suggesting
its possible role in the processing of carcinogens[7].
iNOS contains many sites for prosthetic groups and substrate binding[8],
which are all potentially important for the function of the enzyme.
Furthermore, studies have indicated that even single amino acid
changes may have dramatic effects on enzymatic activity[8,9].
The human iNOS gene comprises 27 exons with the transcription start
site in exon 2 (E2) and the stop codon in E27[10]. E1-13
code for the oxygenase domain, and E1427 encode for the reductase
domain of the protein. Both of the domains represent different
functional parts of the enzyme[9]. Increased iNOS
activities have been observed in patients with chronic gastritis
caused by H pylori infection, and gastric cancer[11,12].
A 13-21 years follow-up study showed that among the H pylori
positive group, the expression of iNOS and nitro-tyrosine was
significantly higher in the group that developed gastric cancer than
the one that showed no evidence of gastric cancer, suggesting that H
pylori positive subjects with high levels of reactive nitrogen
species in gastric mucosa may be a high-risk group for gastric
cancer[13]. Furthermore, recent studies have revealed
that H pylori infection may lead to a sustained production of
reactive nitrogen species and the formation of nitro-tyrosine
contributes to DNA damage and apoptosis in gastric mucosa[12].
Infection with H pylori strains possessing cytotoxin-associated
gene (Cag) A, a molecular marker of H pylori virulence[14,15],
is particularly associated with an increased risk of developing
adenocarcinoma of the stomach. It is suggested that iNOS may be a
susceptible gene involved in the metabolic pathway of nitrogen and
oxygen species of free radicals, and thus may be associated with
both gastric cancer risk and H pylori infection.
Yangzhong city is one of the areas in China with the highest
gastric cancer mortality and incidence rate. The crude mortality
rate of gastric cancer was from 96.9 to 110.9/100 000 during 1991
and 1997, and the average adjusted incidence rate in the same period
was over 115/100 000 (unadjusted rate was 155.46/100 000), which is
over ten times higher than that in the United States[16].
Based on the understanding of the physiology and pathogenesis of
gastric cancer, and the genetic pathway related to H pylori
infection, we hypothesized that higher frequency of iNOS Ser608Leu
allele (i.e. C/T polymorphism)[9,17] was responsible for
the higher gastric cancer incidence in this area. We were especially
interested in knowing whether the association between the
polymorphism and gastric cancer was modified by infection with H
pylori CagA strains and cigarette smoking reflecting high
exposure to nitrogen and oxygen species of free radicals. Therefore,
the aim of this study was to determine whether iNOS C/T polymorphism
was associated with increased susceptibility to gastric cancer, and
the effects of H pylori infection.
MATERIALS
AND METHODS
Study subjects
All
gastric cancer patients and “healthy” controls in this study
were Han ethnic Chinese living in Yangzhong city for at least 25
years. Gastric cancer was diagnosed according to the International
Classification of Diseases for Oncology IX, code = 151, and the
criteria of Laurén[18].
Because most diagnosed gastric cancer cases in Yangzhong were
intestinal type gastric cancer (IGC) and gastric cardia cancer (GCC),
we focused on these two kinds of cancers in the present study. A
population based case-control design was used, and 165 gastric
cancer cases (108 IGC, 57 GCC) and 295 controls were enrolled. The
finally analyzed cases and controls were 143 (93 IGC, 50 GCC) and
246 cases, respectively, because of missing genotype data for some
subjects. There were no significant differences comparing the
finally analyzed subjects and those with missing data by age and
sex. All cases were identified by endoscopic and pathological
diagnosis in Yangzhong City Municipal Hospital from January 1997 to
December 1998. To reduce misclassification of the histological
types, two pathologists reviewed and confirmed all diagnosed cases.
Controls were selected from cancer-free subjects living in the same
community, who were either cases siblings or their non-blood
relatives (spouses and spouses siblings with the same gender as
cases). Both types of controls differed slightly in demographic
features[19]. Their results were combined to increase the
sample size and to decrease type I error. This study was approved by
the regional ethics committee, and all participants were given an
explanation of the nature of the study, and informed consents both
written and oral, were obtained. Study subjects completed a
questionnaire administered by trained interviewers.
The questionnaire was designed to obtain detailed information
on cigarette smoking, alcohol drinking, family history of cancers,
and occupational and hazard exposures. Cigarette smokers were
defined as subjects who reported ever smoking at least one cigarette
per day for 12 mo or more, or whose accumulated cigarette
consumption was over 18 packs per year. Past smokers were those who
had stopped smoking 1 or more years before the interview. Alcohol
drinkers were defined as subjects who reported to have an average of
one drink or more per week for one or more yeaes. Past alcohol
drinkers were also defined as those who had stopped drinking for 1
or more years before the interview.
Laboratory
analysis
Blood was drawn from each participant by the designated
coordinator according to the Guidelines of the National Heart, Lung,
and Blood Institute Working Group on Blood Drawing, Processing, and
Storage for Genetic Studies. Twenty milliliters of forearm venous
blood was collected from each subject via venipuncture into two
10-mL vacutainer tubes containing EDTA. Puragene DNA isolation kits
(Gentra Systems, Minneapolis MN) were used to isolate genomic DNA
for genotyping. All blood samples were separated, and plasma was
collected as soon as possible. The plasma was then stored at -20 °C in six 1.5-mL tubes
for the detection of IgG antibody to H pylori CagA.
Denaturing high performance liquid chromatography (DHPLC) was
used to scan the potential single nucleotide polymorphisms (SNPs) in
all exons of iNOS, and then sequencing was performed to confirm the
possible mutations. Finally, a new C/T polymorphism, which changes
the coding amino acid from serine (TCG) to leucine (TTG), was
identified[17]. PCR-RFLP was carried out to identify the
genotype of iNOS according to the features of SNP, which created a
restriction enzyme recognition site of Tsp 509 I. Genomic DNA was
amplified with primers F: 5’-TGTAAACCAACTTCC GTGGTG-3’ (Tm =
60.82 °C) and R:
5’-GTCTCTGCGGGTCTGAGAAG-3’ (Tm = 60.14 °C). PCR was performed
in a MJRESEARCH PCR system (PTC-225, USA), and in a 10 mL
reaction volume containing 1mL
10×PCR
buffer, 1.6 mL
dNTPs (1.25 mmol/L),
0.2 mL
MgCl2 (25 mmol/L),
primers (20 mmol/L,
Resgen Corp.) at 0.15 mL
each, DMSO 0.5 mL,
6.34 mL
dH2O, 50 ng genomic DNA dried on
the plate, and Hot Start Taq DNA polymerase 0.06 mL
(5 U/mL,
Promega Corp.). Touch down PCR procedure was used to amplify the
target fragment. After an initial denaturation at 94 °C for 15 min,
amplification was carried out for 10 cycles at 94 °C for 30 s, at 61 °C for 45 s, at 72 °C for 45 s and
decreasing 0.5 °C per cycle. Then
amplification was again carried out for 35 cycles at 94 °C for 30 s, at 56 °C for 45 s, and at 72
°C for 45 s, followed
by a final elongation at 72 °C for 7 min. Then, 10
mL
PCR products was digested with
0.2 mL
Tsp
509 I (10 U/mL,
NEB Corp.) in a 15 mL
volume including 2 mL
10×buffer
1 (NEB Corp.), 0.15 mL
BSA (100×)
and 2.65 mL
dH2O. Digestion was performed
for 15 h at 65 °C. The products were
then electrophoresed on a 30 g/L agarose gel to allow unambiguous
detection with ethidium bromide staining. Homozygous wide-type
individuals (CC) showed 113 bp and 175 bp fragments, heterozygous
individuals (CT) showed three bands: 113 bp, 142 bp and 175 bp, and
homozygous rare allele individuals (TT) showed two bands: 113 bp and
142 bp[17].
H pylori CagA IgG antibody in plasma was measured by
an enzyme-linked immunosorbent assay (ELISA) kit offered by Jingying
Biotech Limited Company, Shanghai, China (batch number 0052). The
Absorbency at 450 nm was determined after terminating the enzyme
reaction. The cutoff value equaled to the average A of the negative
controls provided by the manufacturer plus 0.3 A units. A values of
samples equaled to or higher than the cutoff point were considered
positive.
Statistical
analysis
All data were input double blinded into EPI-6 program by two
persons separately. After modifying all errors and non-logical data,
the differences in the relative associations between cases and
controls were assessed by calculating crude odds ratios (OR) from
contingency tables. The corresponding chi-square test on the cancer
patients and controls was carried out, and 95% confidence intervals
(95% CI) were determined using the Fisher exact test. A P-value
<0.05 was considered statistically significant. Unconditional
logistic regression analysis was performed in both univariate and
multivariate models to assess the association between iNOS
functional polymorphism and gastric cancer susceptibility after
adjusting for important confounding factors such as age and sex.
Test of trend and interaction index (g)
that was determined by coefficient (b)
in a multiple logistic regression model were calculated through
logistic models based on dummy variables to examine the potential
gene-environment interaction[20]. All analyses were
performed with the SAS package Genmod (SAS Institute, Cary, NC).
RESULTS
Table 1 compares the characteristics of study subjects. The mean
age of cases was significantly greater than the controls (59.36 vs
51.89, P<0.01). There was no significant difference in the
male/female ratio between cases and controls. The proportions of
past smokers and alcohol drinkers was significantly greater in the
cancer group (36.97% and 30.30%) than in the control group (12.54%
and 14.92%). However, there were more current smokers and drinkers
in the control (47.12% and 30.85%) than in the case group (26.67%
and 10.91%). Compared with controls, cases were significantly less
likely to be positive for H pylori CagA antibody.
The frequency of iNOS genotypes in gastric
cancer and control subjects showed no significant difference,
although the frequency of (CT+TT ) genotypes was slightly higher in
cases than in controls (24.48% versus 23.17%). A gene dose-response
effect was not observed, i.e. the effect of heterozygote (CT)
genotypes did not lie at or between the homozygotes (CC and TT).
For
(CT+TT) the genotype frequency of iNOS in the past smoking subgroup,
there were significant differences between the total cases and the
controls and between GCC group and controls with an OR of 3.62 (95%
CI: 1.23-10.64) and 4.63 (95% CI: 1.15-18.58), respectively. No
significant difference was found between IGC cases and controls
(Table 2). Although no gene dose-response effect was observed in
heterozygote (CT) and homozygote (TT) individuals because of the
small number in each cell, there was still a possible interaction
between C/T polymorphism and past cigarette smoking in increasing
the risk of GCC. In the past alcohol drinkers, there were
significant differences in the C/T polymorphism between total cases
and controls and between IGC group and controls with an OR of 3.33
(95% CI: 1.14-9.67) and 3.42 (95% CI: 1.03-11.35), respectively. No
significant difference between GCC group and control group was found
(Table 3). In H pylori CagA negative group, subjects with (CT+TT)
genotypes had significantly increased risk of both IGC and GCC, with
an OR of 2.19 (95% CI: 1.01-4.76) and 3.52 (95% CI: 1.44-8.61),
respectively. H pylori CagA positivity showed significant
protective effects in IGC group in both on CC and CT+TT iNOS
genotypes, with an OR of 0.24 (95% CI: 0.07-0.89) and 0.34 (95% CI:
0.17-0.70), respectively. However, no significant association
was observed between iNOS genotypes and
GCC (Table 4).
Table
1 Covariate
distribution among study subjects and ORs for gastric cancer
|
Characteristics |
No
Cases (%) (n = 165) |
No.
Controls (%) (n = 295) |
OR
(95% CI) |
| Age
(yr) |
|
|
|
|
|
Mean
(yr±SD) |
59.36±9.29a |
51.89±10.24 |
|
|
Min.
(yr) |
34.72 |
30.77 |
|
|
Max.
(yr) |
81.95 |
78.21 |
|
| Gender |
|
|
|
|
|
Male
(%) |
110
(66.67) |
190
(64.41) |
|
|
Female
(%) |
55
(33.33) |
105
(35.59) |
|
|
Ratio |
2.00:1 |
1.81:1 |
|
| Smoking
habit |
|
|
|
|
|
Never |
60
(36.36) |
119
(40.34) |
1.00 |
|
Current |
44
(26.67) |
139
(47.12) |
0.26
(0.15–0.46)b |
|
Past |
61
(36.97) |
37
(12.54) |
3.15
(1.77–5.61)b |
| Alcohol
habits |
|
|
|
|
|
Never |
97
(58.79) |
160
(54.24) |
1.00 |
|
Current |
18
(10.91) |
91
(30.85) |
0.18
(0.10–0.35)b |
|
Past |
50
(30.30) |
44
(14.92) |
1.80
(1.06–3.08) |
| Plasma
H Pylori CagA antibody |
|
|
|
|
|
Negative |
136
(82.42) |
107
(49.31) |
1.00 |
|
Positive |
29
(17.58) |
110
(50.69) |
0.18
(0.11–0.31)b |
| iNOS
genotyping |
|
|
|
|
|
CC |
108
(75.52) |
189
(76.83) |
1.00 |
|
CT |
33
(23.08) |
49
(19.92) |
1.15
(0.68–1.96) |
|
TT |
2
(1.40) |
8
(3.25) |
0.42
(0.08–2.16) |
|
CT+TT |
35
(24.48) |
57
(23.17) |
1.03
(0.59–1.79) |
aP<0.05
vs control group after adjusted for age and gender, bP<0.01
vs control.
Table
2 Interaction
between C/T polymorphism and past cigarette smoking for the risk of
gastric cancer
| C/T
polymo
rphism |
Past
smoking |
Total
cases (n
= 143) |
Controls
(n = 246) |
OR1 |
95%CI |
IGC
(n = 93) |
OR2 |
95%CI |
GCC
(n = 50) |
OR3 |
95%CI |
| CC |
No |
67 |
162 |
1.00 |
|
|
46 |
1.00 |
21 |
1.00 |
|
| CT+TT |
No |
22 |
51 |
0.98 |
0.55-1.78 |
12 |
0.75 |
0.36-1.54 |
10 |
1.44 |
0.63-3.27 |
| CC |
Yes |
41 |
27 |
2.92 |
1.53-5.57 |
27 |
2.47 |
1.19-5.09 |
14 |
3.65 |
1.42-9.38 |
| CT+TT |
Yes |
13 |
6 |
3.62 |
1.23-10.64 |
8 |
3.06 |
0.91-10.35 |
5 |
4.63 |
1.15-18.58 |
1Adjusted
for age and gender, x2trend
= 26.26, df = 1, P = 0.00, g
= 1.29/1.07 = 1.21 2Adjusted
for age and gender, x2trend
= 18.40, df = 1, P = 0.00, g
= 1.12/0.90 = 1.24 3Adjusted
for age and gender, x2
trend =
17.53, df = 1, P = 0.00, g
= 1.53/1.29 = 1.19.
Table
3 Interaction
between C/T polymorphism and past alcohol drinking for the risk of
gastric cancer
| C/T
polymorphism |
Past
alcohol
drinking |
Total
cases
(n = 143) |
Controls
(n
= 246) |
OR1 |
95%CI |
IGC
(n
= 93) |
OR2 |
95%CI |
GCC
(n
= 50) |
OR3 |
95%CI |
| CC |
No |
76 |
157 |
1.00 |
|
53 |
1.00 |
|
23 |
1.00 |
|
| CT+TT |
No |
24 |
51 |
0.83 |
0.46-1.50 |
13 |
0.62 |
0.30-1.28 |
11 |
1.22 |
0.55-2.70 |
| CC |
Yes |
32 |
32 |
1.34 |
0.72-2.52 |
20 |
1.36 |
0.67-2.75 |
12 |
1.27 |
0.50-3.19 |
| CT+TT |
Yes |
11 |
6 |
3.33 |
1.14-9.67 |
7 |
3.42 |
1.03-11.35 |
4 |
3.25 |
0.80-13.13 |
1Adjusted
for age and gender, x2trend
= 10.29, df = 1, P = 0.001, g
= 1.20/0.30 = 4.00 2Adjusted
for age and gender, x2trend
= 5.65, df = 1, P = 0.017, g
= 1.23/0.31 = 3.97 3Adjusted
for age and gender, x2trend
= 8.95, df = 1, P = 0.003, g
= 1.18/0.24 = 4.9.
Table
4 Interaction
between C/T polymorphism and H pylori CagA status for the
risk of gastric cancer
| C/T
polymorphism |
CagA
antibody |
Total
cases (n
= 143) |
Controls
(n
= 178) |
OR1 |
95%CI |
IGC
(n
= 93) |
OR2 |
95%CI |
GCC
(n = 50) |
OR3 |
95%CI |
| CC |
No |
87 |
64 |
1.00 |
|
61 |
1.00 |
|
26 |
1.00 |
|
| CT+TT |
No |
28 |
19 |
2.53 |
1.29-4.98 |
17 |
2.19 |
1.01-4.76 |
11 |
3.52 |
1.44–8.61 |
| CC |
Yes |
21 |
73 |
0.45 |
0.25-0.81 |
12 |
0.34 |
0.17-0.70 |
9 |
0.76 |
0.33-1.73 |
| CT+TT |
Yes |
7 |
22 |
0.43 |
0.17-1.10 |
3 |
0.24 |
0.07-0.89 |
4 |
0.86 |
0.27-2.79 |
1Adjusted
for age and gender, x2trend
=
33.40, df = 1, P = 0.00, g
=
-0.84/-0.79 = 1.06 2Adjusted
for age and gender, x2trend
=
28.53, df = 1, P = 0.00, g
=
-1.41/-1.08 = 1.31 3Adjusted
for age and gender, x2trend
=
12.42, df = 1, P = 0.0004, g
=
-0.15/-0.27 = 0.56.
DISCUSSION
H
pylori
infection could produce a state of chronic immuno-stimulation in
gastric epithelium[21]. It could lead to changes in many
factors that are important in the pathogenesis of gastric cancer,
including reactive oxygen and nitrogen oxide species [22].
NO, a potentially toxic gas with free radical properties is one of
the most important bio-regulatory and signaling molecules produced
in the process. It has been recently reported that NO, acting as a
messenger molecule mediating various physiological functions[23,24],
may also play a role in the process of carcinogenesis.
It has been found that NO is synthesized enzymatically from
L-arginine by NO synthase[23,25]. Chronic infection and
immuno-stimulation elevate endogenous synthesis of NO. High
concentration of NO generated by macrophages after iNOS induction
contributed to their cytotoxic and carcinogenic activity[26].
There is now increasing evidence that NO produced by activated
phagocytes may play a role in multistage carcinogenesis by mediating
DNA damage[27,28]. A to T substitution in the iNOS gene,
leads to more activated iNOS expression in the target cells, and
finally elevates NO to a high level. Hence, it is reasonable to
assume that human iNOS gene may be another important candidate gene
for the development of gastric cancer by elevating NO production in
target cells when functional polymorphisms occur. Nevertheless its
genomic localization at chromosome 17q11.2[29] was not
the same as other gastric cancer susceptible genes related to the
inflammatory response pathway, such as interleukin 1b
and interleukin 1RN, located at 2q14[30]. The key
question for gastric cancer agents is how H pylori infection
could be associated with such totally divergent clinical outcomes as
gastric cancer and peptic ulcer disease. A large number of previous
studies have focused on the role of the bacterial virulence factors
that contribute to the degree of tissue damage in the pathogenesis
of these diseases. But these results still could not explain the
different outcomes[2,22,31]. With the development of a
key concept about the interaction between acid secretion and H
pylori-induced gastritis during 1990 s, El-Omar proposed the
idea for the first time that host genetic factors relevant to
pro-inflammatory responses might be relevant to the development of
gastric cancer. They explored a candidate IL-1b
gene in the context of H pylori related disease[32,33].
Because IL-1b
can also induce the expression of many other genes, including
pro-inflammatory mediator iNOS, by either regulating at the
transcriptional level or initiating their mRNA[8,9,34],
it is easy to consider that functional polymorphisms occurring in
the iNOS gene might also contribute to the increased risk of H
pylori related gastric cancer.
We
have previously reported a newly discovered C/T polymorphism in a
Chinese population[17] that had a high mutated allele
frequency (24.4%). A report by Johannesen also showed that C/T
polymorphism was one of the most frequent SNPs among 10
polymorphisms of human iNOS gene identified in a Danish population.
They suggested that the amino acid change in exon 16 might be of
functional interest[9]. Our results showed no significant
difference in the frequency of (CT+TT) genotypes between cases and
controls, and no apparent gene dose-response effect was found.
However, in past cigarette smokers and past alcohol drinkers, C/T
polymorphism significantly increased the risk of gastric cancer
despite the histological subtypes differed, i.e. past cigarette
smokers with (CT+TT) genotypes had an increased risk of IGC, while
past alcohol drinkers with (CT+TT) genotypes had increased risk of
GCC. These findings suggest that C/T polymorphism in iNOS gene alone
is not sufficient to show the increasing risk of gastric cancer. The
importance of the interaction between C/T polymorphism and cigarette
smoking or alcohol drinking varied depending on different
histological subtypes of gastric cancer. Similar results were found
by Machado for IL-1 genetic markers[35]. Although these
findings were not the major hypothesis we proposed, it is
biologically plausible that oxidative stress due to carcinogenesis
in cigarette might attribute to the increase of gastric cancer risk
through interactions with iNOS C/T polymorphism. Larger and
independent studies are needed to confirm these findings.
In
the H pylori CagA positive group, regardless of whether
subjects had CC or (CT+TT) genotypes, we always observed a
significant protective effect when comparing IGC cases with
controls. This suggests that plasma positive for H pylori
CagA antibody in a highly infected area plays a protective role.
This is in concordance with the finding that H pylori density
became progressively lower with progression from mild gastritis to
severe gastritis, atrophy, intestinal metaplasia and finally gastric
cancer[29]. In H pylori CagA negative subjects
with (CT+TT) genotypes, a high risk was found for gastric cancer
group (OR = 2.53, 95% CI: 1.29-4.98) and both subgroups (IGC and GCC).
No interaction was found between iNOS genotype and infection with H
pylori CagA strains.
iNOS
protein is a catalytic enzyme with two domains. In terms of
functional importance, the deletion mutants retained maximal NO
activity at lower concentrations of free Ca2+ compared
with the wild-type[36]. Identified C/T polymorphism in
E16 of iNOS was located at the N-terminal of six amino acids from
the deletion reported by Daff et al., and the amino acid
change in E16 might be of functional interest[9]. To our
knowledge, this study was the first one to examine the significance
of iNOS polymorphism in gastric cancer. A research on other type of
disease might support our observation[9]. Gastric cancer
patients having allele T polymorphism could have an increased
expression of iNOS, resulting in higher levels of NO in gastric
mucosa, mediating many pathological changes and finally leading to
carcinogenesis in these patients. But specific functional tests of
C/T shift need to be performed to substantiate the putative
importance of the Ser608Leu locus in gastric cancer development.
Potential weaknesses in our study include possible
recruitment bias in the selection of controls including cases
siblings. This kind of selection might create overmatching. Siblings
were more likely to have the same genotypes as the cases than the
non-blood related controls, thereby leading to some loss of
statistical efficiency, i.e., larger sample sizes were required to
attain the same statistical precision[37]. Thus, our data
may be more likely to underestimate the true effect of iNOS T
alleles on the risk of gastric cancer. But others considered that
the use of sibling controls could generally improve efficiency for
gene-environment interactions[38,39]. We could not rule
out the potential influence of systematic differences between
participants and non-participants.
In conclusion, the risk of gastric cancer is increast among
past cigarette smoking or alcohol drinking individuals with a C/T
polymorphism in E16 of iNOS gene in a Chinese population. But the
findings need to be confirmed in other ethnic populations.
ACKNOWLEDGEMENTS
We thank Zhao-Xi Wang for his excellent technical assistance;
and Professor Regina M. Santella and Dr. Yu-Jing Zhang for editing
the manuscript. We also thank all the doctors for their kind help in
collecting the biological samples and epidemiological data. We thank
all participatants for their co-operation.
REFERENCES
1
Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide
incidence of 25 major cancers in 1990. Int J Cancer
1999; 80: 827-841
2
El-Omar EM, Chow WH, Rabkin CS. Gastric cancer and H
pylori: Host genetics open the way. Gastroenterology
2001; 121:1002-1004
3
Correa P. Human gastric carcinogenesis: a multistep and
multifactorial process-first american cancer society award
lecture on cancer epidemiology and
prevention. Cancer Res 1992; 52:6735-6740
4
Komoto K, Haruma K, Kamada T, Tanaka S, Yoshihara M, Sumii K,
Kajiyama G, Talley NJ. Helicobacter pylori infection
and gastric neoplasia: correlations
with histological gastritis and tumor histology. Am J Gastroenterol
1998; 93: 1271-1276
5
Schistosomes, liver flukes and Helicobacter pylori.
IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans. Lyon, 7-14 June 1994. IARC
Monogr Eval Carcinog Risks Hum 1994; 61: 1-241
6
Felley CP, Pignatelli B, Van Melle GD, Crabtree JE, Stolte M,
Diezi J, Corthesy-Theulaz I, Michetti P, Bancel B, Patricot
LM,
Ohshima H, Felley-Bosco E. Oxidative
stress in gastric mucosa of asymptomatic humans infected with Helicobacter
pylori: effect of
bacterial eradication. Helicobacter 2002; 7: 342-348
7
Vallance P, Collier J. Biology and clinical relevance of
nitric oxide. Br Med J 1994; 309: 453-457
8
Stuehr DJ. Mammalian nitric oxide synthases. Biochim Biophys
Acta 1999; 1411: 217-230
9 Johannesen
J, Pie A, Paiot F, Kristiansen OP, Karlsen AE, Nerup J. Linkage of
the human inducible nitric oxide synthase
gene to type 1 diabetes. J Clin
Endocrinol Metab 2001; 86: 2792-2796
10
Xu W, Charles IG, Liu L, Moncada S, Emson P. Molecular
cloning and structural organization of the human inducible
nitric oxide synthase gene (NOS2).
Biochem Biophys Res Commun 1996; 219: 784-788
11
Mannick EE, Bravo LE, Zarama G, Realpe JL, Zhang XJ, Ruiz B,
Fontham ET, Mera R, Miller MJ, Correa P. Inducible nitric
oxide synthase, nitrotyrosine, and
apoptosis in Helicobacter pylori gastritis: effect of
antibiotics and antioxidants. Cancer
Res 1996; 56: 3238-3243
12
Wee A, Kang JY, Teh M. Helicobacter pylori and gastric
cancer: correlation with gastritis, intestinal metaplasia, and
tumour histology. Gut 1992; 33:
1029-1032
13
Rajnakova A, Goh PM, Chan ST, Ngoi SS, Alponat A, Moochhala
S. Expression of differential nitric oxide synthase
isoforms in human normal gastric
mucosa and gastric cancer tissue. Carcinogenesis 1997; 18: 1841-1845
14
Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM,
Chyou PH, Stemmermann GN, Nomura A. Infection with
Helicobacter pylori
strains possessing CagA is associated with an increased risk of
developing adenocarcinoma of the
stomach. Cancer Res 1995; 55:
2111-2115
15
Goto T, Haruma K, Kitadai Y, Ito M, Yoshihara M, Sumii K,
Hayakawa N, Kajiyama G. Enhanced expression of inducible
nitric oxide synthase and
nitrotyrosine in gastric mucosa of gastric cancer patients. Clin
Cancer Res 1999;5:1411-1415
16
Stadtlander CT, Waterbor JW. Molecular epidemiology,
pathogenesis and prevention of gastric cancer. Carcinogenesis
1999; 20: 2195-2208
17 Shen J, Wang RT, Wand
LW, Wang ZX, Xing HX, Wang BY, Guo CH, Wang XR, Xu XP. Ser/Leu
polymorphism of iNOS
gene was found and identified in
Chinese by denaturing high performance liquid chromatography. Peking
Daxue Xuebao
2001; 33: 486-492
18
Laurén
P. The two
histological main types of gastric carcinoma: diffuse and so-called
intestinal-type carcinoma. An
attempt
at a histo-clinical classification. Acta Pathol Microbiol Scand
1965; 64: 31-49
19
Shen J, Wang R, Wang Z, Xing H, Wang L, Wang B, Li M, Hua Z,
Wang J, Guo C, Wang X, Xu X. The distributive
features
of three kinds of metabolic genes polymorphisms in population of Han
nationality in south area of China.
Zhonghua
Yixue Yichuanxue Zazhi 2002; 19: 302-307
20
Taioli E, Zocchetti C, Garte S. Models of interaction between
metabolic genes and environmental exposure in cancer
susceptibility.
Environ Health Perspect 1998; 106: 67-70
21
Shapiro KB, Hotchkiss JH. Induction of nitric oxide synthesis
in murine macrophages by Helicobacter pylori. Cancer Lett
1996; 102: 49-56
22
El-Omar EM. The importance of interleukin 1 beta in Helicobacter
pylori associated disease. Gut 2001; 48: 743-747
23
Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology,
pathophysiology, and pharmacology. Pharmacol Rev
1991; 43:109-142
24
Son HJ, Rhee JC, Park DI, Kim YH, Rhee PL, Koh KC, Paik SW,
Choi KW, Kim JJ. Inducible nitric oxide synthase
expression in gastroduodenal diseases
infected with Helicobacter pylori. Helicobacter 2001; 6:
37-43
25
Forstermann U, Schmidt HH, Pollock JS, Sheng H, Mitchell JA,
Warner TD, Nakane M, Murad F. Isoforms of nitric oxide
synthase. Characterization and
purification from different cell types. Biochem Pharmacol 1991; 42:
1849-1857
26
Grisham MB, Ware K, Gilleland HE Jr, Gilleland LB, Abell CL,
Yamada T. Neutrophil-mediated nitrosamine formation: role
of nitric oxide in rats.
Gastroenterology 1992; 103: 1260-1266
27
Esumi H, Tannenbaum SR. US-Japan Cooperative Cancer Research
Program: seminar on nitric oxide synthase and
carcinogenesis. Cancer Res 1994; 54:
297-301
28 Ohshima H, Bartsch H.
Chronic infections and inflammatory processes as cancer risk
factors: possible role of nitric oxide
in carcinogenesis. Mutat Res 1994;
305: 253-264
29
Marsden PA, Heng HH, Duff CL, Shi XM, Tsui LC, Hall AV.
Localization of the human gene for inducible nitric oxide
synthase (NOS2) to chromosome
17q11.2-q12. Genomics 1994; 19: 183-185
30
Patterson D, Jones C, Hart I, Bleskan J, Berger R, Geyer D,
Eisenberg SP, Smith MF Jr, Arend WP. The human
interleukin-1 receptor antagonist
(IL1RN) gene is located in the chromosome 2q14 region. Genomics
1993; 15: 173-176
31
Graham DY, Yamaoka Y. Disease-specific Helicobacter pylori
virulence factors: the unfulfilled promise. Helicobacter
2000; 5(Suppl 1): S3-S9
32
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young
HA, Herrera J, Lissowska J, Yuan CC, Rothman N,
Lanyon G, Martin M, Fraumeni JF Jr,
Rabkin CS. Interleukin-1 polymorphisms associated with increased
risk of gastric
cancer. Nature 2000; 404: 398-402
33
El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young
HA, Herrera J, Lissowska J, Yuan CC, Rothman N,
Lanyon G, Martin M, Fraumeni JF Jr,
Rabkin CS. The role of interleukin-1 polymorphisms in the
pathogenesis of gastric
cancer. Nature 2001; 412: 99
34
Cho HJ, Xie QW, Calaycay J, Mumford RA, Swiderek KM, Lee TD,
Nathan C. Calmodulin is a subunit of nitric oxide
synthase from macrophages. J Exp Med
1992; 176: 599-604
35
Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C,
Figueiredo C, Amorim A, Seruca R, Caldas C, Carneiro F,
Sobrinho-Simoes M. Interleukin 1B and
interleukin 1RN polymorphisms are associated with increased risk of
gastric
carcinoma. Gastroenterology 2001;
121: 823-829
36
Daff S, Sagami I, Shimizu T. The 42-amino acid insert in the
FMN domain of neuronal nitric-oxide synthase exerts
control over Ca(2+)/calmodulin-dependent
electron transfer. J Biol Chem 1999; 274: 30589-30595
37
Thomas DC, Witte JS. Point: population stratification: a
problem for case-control studies of candidate-gene
associations? Cancer Epidemiol
Biomark Prev 2002; 11: 505-512
38
Gauderman WJ, Witte JS, Thomas DC. Family-based association
studies. J Natl Cancer Inst Monogr 1999; 26: 31-37
39
Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and
efficiency in case-control studies of candidate genes and
gene-environment interactions: basic
family designs. Am J Epidemiol 1999; 149: 693-705
Edited
by
Xia
HHX and Wang XL Proofread
by Xu FM
| |